Autolus Therapeutics Plc (AUTL) Stock Price & Analysis
Autolus Therapeutics Plc (AUTL) rose 0.00% to USD 1.46 as of June 10, 2026 at 04:38 UTC, according to Nexqual real-time market data.
AUTL last closed at USD 1.46; the session ranged USD 1.38–1.49 on volume of 1,562,842 shares. Market capitalization is $388.57M, with a 52-week range of USD 1.18–2.7 (NMS). Source: Nexqual, June 10, 2026 at 04:38 UTC.
Key Statistics (as of June 10, 2026 at 04:38 UTC)
| Price | USD 1.46 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 1.46 |
| Open | USD 1.48 |
| Day Range | USD 1.38 – 1.49 |
| 52-Week Range | USD 1.18 – 2.7 |
| Volume | 1,562,842 shares |
| Market Cap | $388.57M |
| Exchange | NMS |
Technical Analysis (AUTL)
Nexqual's technical model rates AUTL "NEUTRAL" based on 3 bullish and 4 bearish signals across 123 daily candles, as of June 10, 2026 at 04:38 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 40.32 (neutral) |
| vs SMA50 | Below (USD 1.56) |
| MACD | 0.01 (positive) |
Analyst Ratings (AUTL)
Wall Street analysts rate AUTL "Strong Buy" based on 9 analysts, with a mean price target of USD 8.71 (range USD 5–11), per Nexqual as of June 10, 2026 at 04:38 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 9 |
| Mean Target | USD 8.71 |
| High Target | USD 11 |
| Low Target | USD 5 |
| Buy / Hold / Sell | 9 / 0 / 0 |
Earnings (AUTL)
| Next Earnings Date | 2026-08-14 |
|---|---|
| EPS Estimate | USD -0.23 |
| Revenue Estimate | $30.23M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.27 vs est -0.26 ▼ miss |
| 2025-12-31 | USD -0.34 vs est -0.27 ▼ miss |
| 2025-09-30 | USD -0.3 vs est -0.23 ▼ miss |
| 2025-06-30 | USD -0.18 vs est -0.23 ▲ beat |
Source: Nexqual, June 10, 2026 at 04:38 UTC.
Financials & Fundamentals (AUTL)
| Total Revenue | $1.08M |
|---|---|
| Gross Margin | +0.00% |
| Operating Margin | -6570.75% |
| Profit Margin | +0.00% |
| ROE | -29.62% |
| Current Ratio | 11.05 |
| Total Cash | $217.45M |
| Total Debt | $0 |
Source: Nexqual, June 10, 2026 at 04:38 UTC.
Financial Health Score (AUTL)
Nexqual rates Autolus Therapeutics Plc's overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 04:38 UTC.
| Growth | Strong — Revenue +645% YoY (annual) |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Mixed — $217M cash, no debt |
| Cash Flow | Mixed — No data |
| Efficiency | Critical — ROE -30%, ROA -22.3% |
Ownership (AUTL)
| Insider Ownership | +18.08% |
|---|---|
| Institutional Ownership | +76.21% |
| Shares Outstanding | 266.14M |
| Float | 33.90M |
| Short % of Float | +7.41% |
Source: Nexqual, June 10, 2026 at 04:38 UTC.
Leadership (AUTL)
Autolus Therapeutics Plc is led by Christian Martin Itin (age 61), CEO & Director, per Nexqual as of June 10, 2026 at 04:38 UTC.
| CEO & Director | Christian Martin Itin (age 61) |
|---|---|
| Founder, Senior VP & Chief Scientific Officer | Martin Pule M.D., MBBS (age 53) |
| Senior VP & CFO | Robert F. Dolski (age 54) |
| Senior VP & COO | Christopher Vann (age 60) |
| Senior VP & Chief Technology Officer | Miranda Neville (age 50) |
Major Backers & Investors (AUTL)
Notable institutional backers of Autolus Therapeutics Plc include MAK Capital One LLC, Blackstone Inc, Syncona Portfolio Ltd, according to Nexqual as of June 10, 2026 at 04:38 UTC.
Active Investors
| Investor | Stake |
|---|---|
| MAK Capital One LLC | 12.63% |
| Blackstone Inc | 7.7% |
| Syncona Portfolio Ltd | 6.25% |
| Armistice Capital, LLC | 5.94% |
| Schroder Investment Management Group | 3.57% |
| Tetragon Partners GP Ltd. | 3.57% |
| Frazier Life Sciences Management, L.P. | 1.67% |
| BNP Paribas Asset Management Holding S.A. | 1.26% |
Source: Nexqual, June 10, 2026 at 04:38 UTC.
From Autolus Therapeutics Plc's Latest SEC 10-K Filing (filed 2026-03-27)
Key Strengths & Strategy (as disclosed to the SEC)
- CAR T Cell Production      We have developed our own proprietary viral vector and semi-automated cell manufacturing processes to engineer a patient's T cells with the CAR and other programming modules.
- We believe our scalable closed-system manufacturing process, along with our proprietary and modular T cell programming technologies, would be challenging and costly for potential competitors to replicate.
- Our T cell programming technologies allow us to tailor our therapies to address the specific disease we are targeting and introduce new programming modules into a patient's T cells to give those T cells improved properties to better recognize target cells and overcome fundamental disease defense mechanisms.
- We believe our commercial product and our clinical-stage product candidates and our approach to T cell programming have the potential to address these limitations.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ALLO | Allogene Therapeutics, Inc. | USD 1.82 | ▼ 3.19% |
| MGTX | MeiraGTx Holdings plc | USD 9.21 | ▲ 2.33% |
| BCYC | Bicycle Therapeutics plc | USD 4.17 | ▼ 0.71% |
| CABA | Cabaletta Bio, Inc. | USD 3.22 | ▼ 0.92% |
| CRNX | Crinetics Pharmaceuticals, Inc. | USD 34.97 | ▲ 6.23% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 04:38 UTC. This page is informational and not investment advice.